A Study to Evaluate ALN-4324
Phase 1/2
144
about 2.5 years
18–75
7 sites in CA, DC, FL +3
What this study is about
This trial is testing a treatment called ALN-4324 in two groups of people. One group includes healthy overweight or obese volunteers, and the other group includes adults with type 2 diabetes (T2DM). The goal is to see if this treatment is safe and how it works in both groups.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Take ALN-4324
- 2.Take Placebo
Participation Burden
What's physically and logistically required of participants.
Requires travel to a study site
How treatment is administered
You may get a placebo/standard care, and you won't know which.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
Primary: Part A: Frequency of Adverse Events (AEs), Part B: Frequency of Adverse Events
Secondary: Part A: Area Under the Plasma Concentration-time Curve (AUC) of ALN-4324 in Plasma, Part A: Maximum Observed Plasma Concentration (Cmax) of ALN-4324 in Plasma, Part A: Time to Maximum Plasma Concentration (Tmax) of ALN-4324 in Plasma, Part B: Change from Baseline in HbA1c